报价延迟最少15分钟:2026/03/09 22:00 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
194.95 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
6.54/13.22
|
|
企业价值
629.81B
|
| 资产负债 |
|
每股账面净值
31.38
|
| 现金流量 |
|
现金流量率
0.02
|
| 损益表 |
|
收益
58.74B
|
|
每股收益
29.02
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales. |
